AUKUS details indicate escalating nuclear challenges for Australia, including the local disposal of weapons grade waste and the weakening of a 50-year nuclear
Radiopharm Theranostics Ltd (ASX:RAD) (RAD) has earned a price valuation of $0.70 per share, an implied upside of nearly six times its current share price.